title: Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies.
abstract: In the treatment of metastatic colorectal cancer, the subset of patients with liver-only metastases shows the greatest promise for prolonged survival and cure. Advances in surgery and medical treatment have encouraged multimodality treatment strategies and therefore require a true multidisciplinary approach. The current standard of care includes peri-operative chemotherapy and surgery. The new era of biologically targeted therapy requires an in-depth look at the possible efficacy and risks of adding these agents to the treatment protocol.
authors.affiliation: Department of Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium.
authors.forename: Ravit
authors.initials: R
authors.lastname: Geva
authors.forename: Hans
authors.initials: H
authors.lastname: Prenen
authors.forename: Baki
authors.initials: B
authors.lastname: Topal
authors.forename: Raymond
authors.initials: R
authors.lastname: Aerts
authors.forename: Jaarke
authors.initials: J
authors.lastname: Vannoote
authors.forename: Eric
authors.initials: E
authors.lastname: Van Cutsem
mesh_terms: D000906:Antibodies; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000276:immunology*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary / Q000601:surgery; D008297:Male; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology*
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab